Duke Cancer Center

Running trials

• Not yet recruiting

  Phase 3 Trial of SRG-514 Administered Intraoperatively to Patients Undergoing Breast-Conserving Surgery

  NCT07723469· Phase 3· Source

• Recruiting

  Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

  NCT07621718· Phase 3· Source

• Recruiting

  A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

  NCT07124078· Phase 2· Source

• Recruiting

  A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

  NCT07280013· Phase 1· Source

• Recruiting

  Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT07252232· Phase 3· Source

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Source

• Recruiting

  Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

  NCT07227012· Phase 1/2· Source

• Recruiting

  A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

  NCT07103018· Phase 1· Source

• Recruiting

  AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

  NCT07094113· Phase 1· Source

• Recruiting

  Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

  NCT06765109· Phase 3· Source

• Recruiting

  REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors

  NCT06710548· Source

• Recruiting

  CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

  NCT06690775· Phase 2· Source

• Recruiting

  PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

  NCT05096481· Phase 2· Source

• Recruiting

  Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

  NCT06252649· Phase 3· Source

• Recruiting

  VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]

  NCT06264180· Phase 3· Source

• Recruiting

  A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)

  NCT06263231· Phase 3· Source

• Recruiting

  Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

  NCT05659381· Phase 3· Source

• Recruiting

  A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  NCT06161025· Phase 2/3· Source

• Active, not recruiting

  A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

  NCT06111235· Phase 3· Source

• Active, not recruiting

  ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

  NCT05682443· Phase 1/2· Source

• Recruiting

  BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

  NCT06120283· Phase 1· Source

• Recruiting

  Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

  NCT06040541· Phase 1· Source

• Active, not recruiting

  Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

  NCT05611931· Phase 3· Source

• Recruiting

  Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

  NCT05482893· Phase 1/2· Source

• Active, not recruiting

  A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

  NCT05609370· Phase 1/2· Source

• Active, not recruiting

  A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma

  NCT04971499· Phase 1/2· Source

• Active, not recruiting

  Cardiac Outcomes With Near-Complete Estrogen Deprivation

  NCT05309655· Source

• Active, not recruiting

  A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

  NCT05335993· Phase 2· Source

• Recruiting

  A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer

  NCT04831580· Source

• Recruiting

  Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

  NCT05098132· Phase 1/2· Source

• Recruiting

  CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

  NCT05143996· Phase 1/2· Source

• Recruiting

  A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

  NCT04729114· Phase 1· Source

• Active, not recruiting

  Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

  NCT04703192· Phase 2· Source

• Recruiting

  A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

  NCT04775485· Phase 2· Source

• Recruiting

  Interventional Radiology Liver Directed Therapies and Hypofractionated Image-Guided Radiation Therapy in Veteran and Non-Veteran, Non-surgical Hepatocellular Carcinoma Patients

  NCT04933435· Source

• Enrolling by invitation

  Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19

  NCT04357574· Source

• Active, not recruiting

  Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

  NCT03485209· Phase 2· Source

• Active, not recruiting

  Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

  NCT03767348· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer5 recruiting
• Pancreatic cancer5 recruiting
• Childhood cancers3 recruiting
• Liver and biliary tract cancer3 recruiting
• Lung cancer3 recruiting
• Ovarian cancer3 recruiting
• Prostate cancer2 recruiting
• Acute myeloid leukaemia1 recruiting
• Cervical cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Melanoma1 recruiting
• Metastatic breast cancer1 recruiting
• Multiple myeloma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Sarcoma1 recruiting
• Triple-negative breast cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Withdrawn

  Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC)

  NCT06603155· Source

• Withdrawn

  SRS Timing With Immune Checkpoint Inhibition in Patients With Untreated Brain Metastases From Non-small Cell Lung Cancer

  NCT04650490· Phase 2· Source

• Withdrawn

  177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)

  NCT04315246· Phase 1/2· Source

• Terminated

  To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

  NCT04551053· Phase 3· Source

• Terminated

  To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

  NCT04551066· Phase 3· Source

• Completed

  Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)

  NCT04799249· Phase 3· Source

• Completed

  Actuate 1901: 9-ING-41 in Myelofibrosis

  NCT04218071· Phase 2· Source

• Completed

  An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

  NCT03915951· Phase 2· Source

• Terminated

  A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma

  NCT03866239· Phase 1· Source

• Completed

  PaRTNer: Patient Reported Outcomes and Financial Toxicity in Head and Neck Cancer A Pilot, Survey Based Study

  NCT03506451· Source

• Completed

  PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

  NCT03269136· Phase 1· Source

• Completed

  Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)

  NCT03064490· Phase 2· Source

• Recruiting

  Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

  NCT02074839· Phase 1· Source